Consumer Health Cancer / Oncology
Australia First in-human use of OncoRes Medical's cancer imaging system successful
OncoRes Medical today announces positive data from the first in-cavity use of its Quantitative Micro-Elastography (QME) Imaging System. The study, titled&n...
November 03, 2022 | News
Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy
If adopted, the rule would eliminate all cost to Medicare patients for a follow-up colonoscopy after a positive at-home colorectal cancer screening test. A...
November 02, 2022 | News
Irish oncology care platform announces collaboration with NCCN
The Irish-founded oncology software company, ONCOassist, today announces a new agreement with The National Comprehensive Cancer Network® (NCCN®). T...
October 18, 2022 | News
Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging
The IND application was submitted in partnership with Grand Pharmaceutical Group Limited (Grand Pharma), Telix's partner in the Greater China reg...
October 17, 2022 | News
Health Canada Approves Illuccix® for Prostate Cancer Imaging
Illuccix™ [kit for the preparation of gallium (68Ga) gozetotide injection], after radiolabeling with gallium (68Ga), is indicated for use with the po...
October 14, 2022 | News
First patient treated in Clarity's therapeutic prostate cancer trial
Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT0...
October 10, 2022 | News
China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...
October 10, 2022 | News
First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent
As Illuccix rolls out to positron emission tomography (PET) sites across the country, Mercy Radiology in Auckland became the first to administer ...
September 30, 2022 | News
Australia approved New treatment for rare cancer cholangiocarcinoma
A NEW targeted therapy to treat a rare bile duct cancer called cholangiocarcinoma has been approved for use in Australia. PEMAZYRE® (pemigat...
September 16, 2022 | News
Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients
First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...
September 14, 2022 | News
SeekIn Receives CE Mark Approval for OncoSeek® Multi-Cancer Detection Test
SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approva...
September 13, 2022 | News
Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive early data for two novel and investigational bispecific antibodies – uba...
September 12, 2022 | News
Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients
Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unres...
September 08, 2022 | News
Zhongchao Inc. Announces its New Strategy Extension Focusing on the Oncology and Other Major Disease Management
Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare inform...
September 02, 2022 | News
Most Read
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
